on the basis of these reports and laboratory data suggesting activity for recombinant gamma-interferon ( r-gifn ) against several malignant cell lines , we treated 27 refractory ovarian carcinoma patients , including six with very-small-volume residual disease , with this agent delivered by the ip route .
C0334227
malignant cell
C0677936
refractory